Final Logo-01.png
Remicade Biosimilars Market Size & Share to Exceed USD 34.4 Billion by 2034, at CAGR of 9.30% - By PMI
February 08, 2024 17:30 ET | PMI
Covina, Feb. 08, 2024 (GLOBE NEWSWIRE) -- “According to the recent research study, the Remicade Biosimilars Market size was valued at about USD 15.3 Billion in 2024 and expected to grow at CAGR of...
Final Logo-01.png
Axial Spondyloarthritis Market Awareness Campaigns Promote Early Diagnosis and Improved Outcomes – By PMI
October 17, 2023 13:30 ET | PMI
Covina, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Axial Spondyloarthritis affects joints in axial skeleton such as chest, pelvis and spine. Skin and nail changes of Psoriasis, longstanding low back pain,...
FATE Alert: Monsey Law Firm of Wohl & Fruchter LLP Investigating Potential Securities Claims Against Fate Therapeutics, Inc.
January 05, 2023 20:00 ET | Wohl & Fruchter LLP
MONSEY, N.Y., Jan. 05, 2023 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating whether Fate Therapeutics, Inc. (Nasdaq: FATE) (“FATE”) violated federal securities laws in...
FStar.jpg
F-star Therapeutics Announces License Agreement with Janssen to Develop and Commercialize Multiple Next Generation Bispecific Antibody Therapeutics
October 20, 2021 08:00 ET | F-star Therapeutics, Inc.
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Ltd. (NASDAQ: FSTX) (“F-star” or the “Company”), a clinical-stage biopharmaceutical company...